Tag CIMERLI

Company News, News

Sandoz has completed the acquisition of the US biosimilar CIMERLI®

Sandoz has completed the acquisition of the US biosimilar CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of anticipated timelines. The acquisition builds on the leading Sandoz ophthalmic platform in the US and lays an even stronger foundation for future product…

March 4, 2024

Company News, News

Sandoz has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI® from Coherus BioSciences.

Sandoz has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences, for an upfront cash purchase payment of USD 170 million. This agreement is inclusive of a biologics license application, product inventory, ophthalmology sales and…

January 22, 2024